Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Mar;73(5):610–614. doi: 10.1038/bjc.1996.105

Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression.

T L Walker 1, J D White 1, W J Esdale 1, M A Burton 1, E E DeCruz 1
PMCID: PMC2074343  PMID: 8605094

Abstract

The c-myc oncogene has been extensively implicated in cell proliferation, cell differentiation and programmed cell death. Aberrant expression of the c-myc gene product has been observed in a range of tumours and has also been implicated in cisplatin (cis-dichlorodiammineplatinum)-mediated chemoresistance. A solid transplantable tumour model in syngeneic DA rats was subjected to treatment with cisplatin to determine the impact of such therapy on endogenous c-myc gene expression. Serially transplanted tumours were intravenously treated with a single cisplatin dose (1 mg/kg) and c-myc expression analysed 2 and 7 days after treatment. The surviving tumour cells display a significant 2-fold elevation in c-myc expression at 48 h and 7 days after treatment. Primary cell cultures have been derived from untreated in vivo tumours of the same model and subjected to treatment with a c-myc phosphorothioate antisense oligomer. Administration of 5 microM c-myc antisense oligomer directed at the initiation codon and first four codons of c-myc mRNA results in total inhibition of c-myc expression and coincident suspension of cell growth for a period of 4 days in culture. Antisense therapies directed at the c-myc gene may well prove an effective tool for treating tumours in conjunction with cisplatin as these findings show that tumour cells surviving cisplatin chemotherapy display elevated c-myc expression.

Full text

PDF
610

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrews P. A., Howell S. B. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells. 1990 Feb;2(2):35–43. [PubMed] [Google Scholar]
  2. Biro S., Fu Y. M., Yu Z. X., Epstein S. E. Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):654–658. doi: 10.1073/pnas.90.2.654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chougule P. B., Suk S., Chu Q. D., Leone L., Nigri P. T., McRae R., Lekas M., Barone A., Bhat D., Bellino J. Cisplatin as a radiation sensitizer in the treatment of advanced head and neck cancers. Results of a phase II study. Cancer. 1994 Oct 1;74(7):1927–1932. doi: 10.1002/1097-0142(19941001)74:7<1927::aid-cncr2820740717>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  4. Christen R. D., Jekunen A. P., Jones J. A., Thiebaut F., Shalinsky D. R., Howell S. B. In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules. J Clin Invest. 1993 Jul;92(1):431–440. doi: 10.1172/JCI116585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Eichholtz-Wirth H., Reidel G., Hietel B. Radiation-induced transient cisplatin resistance in murine fibrosarcoma cells associated with elevated metallothionein content. Br J Cancer. 1993 May;67(5):1001–1006. doi: 10.1038/bjc.1993.183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fraval H. N., Roberts J. J. G1 phase chinese hamster V79-379A cells are inherently more sensitive to platinum bound to their DNA than mid S phase or asynchronously treated cells. Biochem Pharmacol. 1979 May 15;28(10):1575–1580. doi: 10.1016/0006-2952(79)90167-9. [DOI] [PubMed] [Google Scholar]
  7. Funato T., Yoshida E., Jiao L., Tone T., Kashani-Sabet M., Scanlon K. J. The utility of an anti-fos ribozyme in reversing cisplatin resistance in human carcinomas. Adv Enzyme Regul. 1992;32:195–209. doi: 10.1016/0065-2571(92)90017-t. [DOI] [PubMed] [Google Scholar]
  8. Gately D. P., Howell S. B. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer. 1993 Jun;67(6):1171–1176. doi: 10.1038/bjc.1993.221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Godwin A. K., Meister A., O'Dwyer P. J., Huang C. S., Hamilton T. C., Anderson M. E. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3070–3074. doi: 10.1073/pnas.89.7.3070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hanson K. D., Shichiri M., Follansbee M. R., Sedivy J. M. Effects of c-myc expression on cell cycle progression. Mol Cell Biol. 1994 Sep;14(9):5748–5755. doi: 10.1128/mcb.14.9.5748. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hay N., Takimoto M., Bishop J. M. A FOS protein is present in a complex that binds a negative regulator of MYC. Genes Dev. 1989 Mar;3(3):293–303. doi: 10.1101/gad.3.3.293. [DOI] [PubMed] [Google Scholar]
  12. Hayashi K., Makino R., Kawamura H., Arisawa A., Yoneda K. Characterization of rat c-myc and adjacent regions. Nucleic Acids Res. 1987 Aug 25;15(16):6419–6436. doi: 10.1093/nar/15.16.6419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Heikkila R., Schwab G., Wickstrom E., Loke S. L., Pluznik D. H., Watt R., Neckers L. M. A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1. 1987 Jul 30-Aug 5Nature. 328(6129):445–449. doi: 10.1038/328445a0. [DOI] [PubMed] [Google Scholar]
  14. Hermeking H., Eick D. Mediation of c-Myc-induced apoptosis by p53. Science. 1994 Sep 30;265(5181):2091–2093. doi: 10.1126/science.8091232. [DOI] [PubMed] [Google Scholar]
  15. Isonishi S., Hom D. K., Thiebaut F. B., Mann S. C., Andrews P. A., Basu A., Lazo J. S., Eastman A., Howell S. B. Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin. Cancer Res. 1991 Nov 1;51(21):5903–5909. [PubMed] [Google Scholar]
  16. Iversen P. In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue. Anticancer Drug Des. 1991 Dec;6(6):531–538. [PubMed] [Google Scholar]
  17. Kasahara K., Fujiwara Y., Nishio K., Ohmori T., Sugimoto Y., Komiya K., Matsuda T., Saijo N. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res. 1991 Jun 15;51(12):3237–3242. [PubMed] [Google Scholar]
  18. Kashani-Sabet M., Lu Y., Leong L., Haedicke K., Scanlon K. J. Differential oncogene amplification in tumor cells from a patient treated with cisplatin and 5-fluorouracil. Eur J Cancer. 1990 Mar;26(3):383–390. doi: 10.1016/0277-5379(90)90238-o. [DOI] [PubMed] [Google Scholar]
  19. Kato G. J., Lee W. M., Chen L. L., Dang C. V. Max: functional domains and interaction with c-Myc. Genes Dev. 1992 Jan;6(1):81–92. doi: 10.1101/gad.6.1.81. [DOI] [PubMed] [Google Scholar]
  20. Kelland L. R., Mistry P., Abel G., Loh S. Y., O'Neill C. F., Murrer B. A., Harrap K. R. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res. 1992 Jul 15;52(14):3857–3864. [PubMed] [Google Scholar]
  21. Kotake T., Saiki S., Kinouchi T., Shiku H., Nakayama E. Detection of the c-myc gene product in urinary bladder cancer. Jpn J Cancer Res. 1990 Dec;81(12):1198–1201. doi: 10.1111/j.1349-7006.1990.tb02677.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Lotem J., Sachs L. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ. 1993 Jan;4(1):41–47. [PubMed] [Google Scholar]
  23. Marazzi L., Parodi M. T., Di Martino D., Ferrari S., Tonini G. P. Coordinate change of c-myc, transferrin receptor and H3 gene expression precedes induction of haemoglobin-producing cells of the leukaemia K562 cell line treated with cis-diamminedichloroplatinum (II). Anticancer Res. 1991 Mar-Apr;11(2):947–952. [PubMed] [Google Scholar]
  24. Markman M. Current status of intraperitoneal therapy for ovarian cancer. Curr Opin Obstet Gynecol. 1993 Feb;5(1):99–104. [PubMed] [Google Scholar]
  25. Mizutani Y., Fukumoto M., Bonavida B., Yoshida O. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide. Cancer. 1994 Nov 1;74(9):2546–2554. doi: 10.1002/1097-0142(19941101)74:9<2546::aid-cncr2820740924>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  26. Napoli S., Burton M. A., Martins I. J., Chen Y., Codde J. P., Gray B. N. Dose response and toxicity of doxorubicin microspheres in a rat tumor model. Anticancer Drugs. 1992 Feb;3(1):47–53. doi: 10.1097/00001813-199202000-00009. [DOI] [PubMed] [Google Scholar]
  27. Niimi S., Nakagawa K., Yokota J., Tsunokawa Y., Nishio K., Terashima Y., Shibuya M., Terada M., Saijo N. Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes. Br J Cancer. 1991 Feb;63(2):237–241. doi: 10.1038/bjc.1991.56. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Osmak M. Multifactorial molecular mechanisms are involved in resistance of preirradiated human cervix carcinoma cells to cis-dichlorodiammineplatinum (II) and vincristine. Neoplasma. 1993;40(2):97–101. [PubMed] [Google Scholar]
  29. Paria B. C., Dey S. K., Andrews G. K. Antisense c-myc effects on preimplantation mouse embryo development. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10051–10055. doi: 10.1073/pnas.89.21.10051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Rubin E., Kharbanda S., Gunji H., Weichselbaum R., Kufe D. cis-Diamminedichloroplatinum(II) induces c-jun expression in human myeloid leukemia cells: potential involvement of a protein kinase C-dependent signaling pathway. Cancer Res. 1992 Feb 15;52(4):878–882. [PubMed] [Google Scholar]
  31. Scanlon K. J., Kashani-Sabet M. Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells. Proc Natl Acad Sci U S A. 1988 Feb;85(3):650–653. doi: 10.1073/pnas.85.3.650. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Shaw P., Bovey R., Tardy S., Sahli R., Sordat B., Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci U S A. 1992 May 15;89(10):4495–4499. doi: 10.1073/pnas.89.10.4495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Shichiri M., Hanson K. D., Sedivy J. M. Effects of c-myc expression on proliferation, quiescence, and the G0 to G1 transition in nontransformed cells. Cell Growth Differ. 1993 Feb;4(2):93–104. [PubMed] [Google Scholar]
  34. Sklar M. D., Prochownik E. V. Modulation of cis-platinum resistance in Friend erythroleukemia cells by c-myc. Cancer Res. 1991 Apr 15;51(8):2118–2123. [PubMed] [Google Scholar]
  35. Smith D. R., Myint T., Goh H. S. Over-expression of the c-myc proto-oncogene in colorectal carcinoma. Br J Cancer. 1993 Aug;68(2):407–413. doi: 10.1038/bjc.1993.350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Spandidos D. A., Zoumpourlis V., Lang J. C. Cis-platin responsive sequences in the human c-myc promoter. Anticancer Res. 1991 May-Jun;11(3):1339–1342. [PubMed] [Google Scholar]
  37. Spencer C. A., Groudine M. Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res. 1991;56:1–48. doi: 10.1016/s0065-230x(08)60476-5. [DOI] [PubMed] [Google Scholar]
  38. Stein C. A., Cheng Y. C. Antisense oligonucleotides as therapeutic agents--is the bullet really magical? Science. 1993 Aug 20;261(5124):1004–1012. doi: 10.1126/science.8351515. [DOI] [PubMed] [Google Scholar]
  39. Tashiro H., Miyazaki K., Okamura H., Iwai A., Fukumoto M. c-myc over-expression in human primary ovarian tumours: its relevance to tumour progression. Int J Cancer. 1992 Mar 12;50(5):828–833. doi: 10.1002/ijc.2910500528. [DOI] [PubMed] [Google Scholar]
  40. Taverna P., Hansson J., Scanlon K. J., Hill B. T. Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity. Carcinogenesis. 1994 Sep;15(9):2053–2056. doi: 10.1093/carcin/15.9.2053. [DOI] [PubMed] [Google Scholar]
  41. Toffoli G., Viel A., Tumiotto L., Biscontin G., Rossi C., Boiocchi M. Pleiotropic-resistant phenotype is a multifactorial phenomenon in human colon carcinoma cell lines. Br J Cancer. 1991 Jan;63(1):51–56. doi: 10.1038/bjc.1991.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Twentyman P. R., Wright K. A., Rhodes T. Radiation response of human lung cancer cells with inherent and acquired resistance to cisplatin. Int J Radiat Oncol Biol Phys. 1991 Feb;20(2):217–220. doi: 10.1016/0360-3016(91)90093-j. [DOI] [PubMed] [Google Scholar]
  43. Volm M., Drings P., Wodrich W., van Kaick G. Expression of oncoproteins in primary human non-small cell lung cancer and incidence of metastases. Clin Exp Metastasis. 1993 Jul;11(4):325–329. doi: 10.1007/BF00058052. [DOI] [PubMed] [Google Scholar]
  44. Watson P. H., Safneck J. R., Le K., Dubik D., Shiu R. P. Relationship of c-myc amplification to progression of breast cancer from in situ to invasive tumor and lymph node metastasis. J Natl Cancer Inst. 1993 Jun 2;85(11):902–907. doi: 10.1093/jnci/85.11.902. [DOI] [PubMed] [Google Scholar]
  45. Yagoda A., Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993 Feb 1;71(3 Suppl):1098–1109. doi: 10.1002/1097-0142(19930201)71:3+<1098::aid-cncr2820711432>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES